Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months

Table 4 Relations between pre-ER and Pathological Response in Tumor Site

	DFS		OS
Variables	No.(%)	Log-Rank P	No.(%)	Log-Rank P
Before surgery
Age
≤ 50	30(41.7%)		36(41.4%)
>50	42(58.3%)	0.792	51(58.6%)	0.638
Clinial stage
II B	20(27.8%)		23(26.4%)
III A	34(47.2%)		39(44.9%)
III B	14(19.4%)		18(20.7%)
III C	4(5.6%)	0.517	7(8.0%)	0.195
cALN
negative	21(29.2%)		25(28.7%)
positive	51(70.8%)	0.522	62(71.3%)	0.295
ER
negative	33(45.8%)		37(42.5%)
positive	39(54.2%)	0.580	50(57.5%)	0.045
PR
negative	32(44.4%)		38(43.7%)
positive	40(55.6%)	0.155	49(56.3%)	0.026
HER-2
0-2+	52(72.2%)		63(72.4%)
3+	20(27.8%)	0.778	24(27.6%)	0.643
Ki67
≤ 20%	49(68.1%)		58(66.7%)
>20%	23(31.9%)	0.071	29(34.3%)	0.055
Pathology
IDC	57(79.1%)		69(79.3%)
ILC	2(2.8%)		2(2.3%)
other	13(18.1%)	0.987	16(18.4%)	0.934
Clinical response
CR	20(27.8%)		11((12.6%)
PR	44(61.1%)		54(62.2%)
SD	7(9.7%)		21(24.1%)
PD	1(1.4%)	0.284	1(1.1%)	0.651
After surgery
cALN
negative	49(68.1%)		60(69.0%)
positive	23(31.9%)	0.848	27(31.0%)	0.912
ER※
negative	55(76.4%)		67(77.0%)
positive	17(23.6%)	0.965	20(23.0%)	0.827
PR※
negative	54(75.0%)		67(77.0%)
positive	18(25.0%)	0.428	20(23.0%)	0.864
HER-2※
0-2+	50(69.4%)		60(69.0%)
3+	22(30.6%)	0.568	27(31.0%)	0.328
Ki67※
≤ 20%	66(91.7%)		80(92.0%)
>20%	6(8.3%)	0.025	7(8.0%)	0.001
pALN
N 0	23(31.9%)		27(31.0%)
N 1-3	18(25.0%)		20(23.0%)
N 4-9	18(25.0%)		23(26.5%)
N >9	13(18.1%)	0.456	17(19.5%)	0.425
Pathological tumor size
≤ 2 cm	14(19.4%)		18(20.7%)
> 2 cm	41(56.9%)		48(55.2%)
unmeasured	17(23.7%)	0.256	21(24.1%)	0.303
Grade
I	1(1.4%)		1(1.2%)
II	39(54.2%)		47(54.0%)
III	8(11.1%)		11(12.6%)
Not graded	24(33.3%)	0.624	28(32.2%)	0.827
pathological response in tumor site
pCR	21(29.2%)		22(25.3%)
non-pCR	51(70.8%)	<0.001	65(74.7%)	0.003

Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.
※109 patients were evaluated after neoadjuvant chemotherapy, because of 10 patients with no residual tumor in postoperative tissue.
*115 Patients were evaluable for survival (4 patients were lost to follow-up)

ISSN: 1471-2407